Cited by 697Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatmentsMedical Imaging Techniques and Applications

The DOI matches its Crossref record; 34 of the 35 references it cites were found in a registry or an index.

In Vivo Imaging of Amyloid Deposition in Alzheimer Disease Using the Radioligand 18 F-AV-45 (Flobetapir F 18)

Open access

Wong, Dean F., Rosenberg, Paul B., Zhou, Yun, Kumar, Anil, Raymont, Vanessa, Ravert, Hayden T., Dannals, Robert F., Nandi, Ayon, Brašić, James R., Ye, Weiguo, Hilton, John, Lyketsos, Constantine, Kung, Hank F., Joshi, Abhinay D., Skovronsky, Daniel M., Pontecorvo, Michael J.·2010·Journal of Nuclear Medicine

DOI 10.2967/jnumed.109.069088PMC PMC3101877

Open this paper in CoChat — free account Open PDF

Abstract

UNLABELLED: An (18)F-labeled PET amyloid-beta (Abeta) imaging agent could facilitate the clinical evaluation of late-life cognitive impairment by providing an objective measure for Alzheimer disease (AD) pathology. Here we present the results of a clinical trial with (E)-4-(2-(6-(2-(2-(2-(18)F-fluoroethoxy)ethoxy)ethoxy)pyridin-3-yl)vinyl)-N-methyl benzenamine ((18)F-AV-45 or florbetapir [corrected] F 18). METHODS: An open-label, multicenter brain imaging, metabolism, and safety study of (18)F-AV-45 was performed on 16 patients with AD (Mini-Mental State Examination score, 19.3 +/- 3.1; mean age +/- SD, 75.8 +/- 9.2 y) and 16 cognitively healthy controls (HCs) (Mini-Mental State Examination score, 29.8 +/- 0.45; mean age +/- SD, 72.5 +/- 11.6 y). Dynamic PET was performed over a period of approximately 90 min after injection of the tracer (370 MBq [10 mCi]). Standardized uptake values and cortical-to-cerebellum standardized uptake value ratios (SUVRs) were calculated. A simplified reference tissue method was used to generate distribution volume ratio (DVR) parametric maps for a subset of subjects. RESULTS: Valid PET data were available for 11 AD patients and 15 HCs. (18)F-AV-45 accumulated in cortical regions expected to be high in Abeta deposition (e.g., precuneus and frontal and temporal cortices) in AD patients; minimal accumulation of the tracer was seen in cortical regions of HCs. The cortical-to-cerebellar SUVRs in AD patients showed continual substantial increases through 30 min after administration, reaching a plateau within 50 min. The 10-min period from 50 to 60 min after administration was taken as a representative sample for further analysis. The cortical average SUVR for this period was 1.67 +/- 0.175 for patients with AD versus 1.25 +/- 0.177 for HCs. Spatially normalized DVRs generated from PET dynamic scans were highly correlated with SUVR (r = 0.58-0.88, P < 0.005) and were significantly greater for AD patients than for HCs in cortical regions but not in subcortical white matter or cerebellar regions. No clinically significant changes in vital signs, electrocardiogram, or laboratory values were observed. CONCLUSION: (18)F-AV-45 was well tolerated, and PET showed significant discrimination between AD patients and HCs, using either a parametric reference region method (DVR) or a simplified SUVR calculated from 10 min of scanning 50-60 min after (18)F-AV-45 administration.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.2967/jnumed.109.069088

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

“Mini-mental state”
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282 · cited 1×
“Patients with AD had to be older than 50 y and have a probable diagnosis of AD according to the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer’s Disease and Related Disorders Association, with a Mini-Mental State Examination (MMSE) score of between 10 and 24, inclusively (1…”
Method
The precuneus: a review of its functional anatomy and behavioural correlates
Cavanna, A. E., & Trimble, M. R. (2006) · Brain · doi:10.1093/brain/awl004 · Cited by 5,128 · cited 1×
“This finding is consistent with the known localization of Ab in these areas in postmortem tissue (23), with recent literature suggesting the precuneus is involved in integrative functions including visual spatial coordination and working memory retrieval (24)—and with results from other Ab radiotracers (9,25).”
Result
The Consortium to Establish a Registry for Alzheimer's Disease (CERAD): Part II. Standardization of the neuropathologic assessment of Alzheimer's disease
Mirra, S. S., Heyman, A., McKeel, D., Sumi, S. M., Crain, B. J., Brownlee, L. M., Vogel, F. S., Hughes, J. P., Belle, G. V., Berg, L., et al. (1991) · Neurology · doi:10.1212/wnl.41.4.479 · Cited by 4,961
Consortium to Establish a Registry for Alzheimer's Disease (CERAD)
Fillenbaum, G., & Heyman, A. (2002) · doi:10.1002/0470846410.ch42(iii · Cited by 2,859
Editorial on Consensus Recommendations for the Postmortem Diagnosis of Alzheimer Disease from the National Institute on Aging and the Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer Disease
HYMAN, B. T., & TROJANOWSKI, J. Q. (1997) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199710000-00002 · Cited by 1,542
OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine.
Stabin, M. G., Sparks, R. B., & Crowe, E. A. (2005) · PubMed · Cited by 1,340
[ 11 C]PIB in a nondemented population: Potential antecedent marker of Alzheimer disease
Mintun, M. A., LaRossa, G. N., Sheline, Y. I., Dence, C. S., Lee, S. Y., Mach, R. H., Klunk, W. E., Mathis, C. A., DeKosky, S. T., & Morris, J. C. (2006) · Neurology · doi:10.1212/01.wnl.0000228230.26044.a4 · Cited by 1,036 · cited 3×
“This pattern is similar to that previously reported for 11CPIB (21,22) and 18F-BAY94-9172 (9).”
BackgroundResult
Cerebrospinal Fluid tau/β-Amyloid42 Ratio as a Prediction of Cognitive Decline in Nondemented Older Adults
Fagan, A. M., Roe, C. M., Xiong, C., Mintun, M. A., Morris, J. C., & Holtzman, D. M. (2007) · Archives of Neurology · doi:10.1001/archneur.64.3.noc60123 · Cited by 897 · cited 1×
“Although cerebrospinal fluid Ab levels are reliably decreased in AD (6), cerebrospinal fluid studies are inevitably indirect markers.”
Background
-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease
Pike, K. E., Savage, G., Villemagne, V. L., Ng, S., Moss, S. A., Maruff, P., Mathis, C. A., Klunk, W. E., Masters, C. L., & Rowe, C. C. (2007) · Brain · doi:10.1093/brain/awm238 · Cited by 789
Antibodies against β-Amyloid Slow Cognitive Decline in Alzheimer's Disease
Höck, C., Konietzko, U., Streffer, J. R., Tracy, J., Signorell, A., Müller-Tillmanns, B., Lemke, U., Henke, K., Moritz, E., Garcia, E., et al. (2003) · Neuron · doi:10.1016/s0896-6273(03)00294-0 · Cited by 786

Show all 35 references

Research works printed but not linked: 4

2005, J Nucl Med., 46, 1023
2005, J Nucl Med., 46, 1959
1997, Int Psychogeriatr., 9, 257
2008, J Nucl Med., 49, 283P

Sorted by citations

Items 301–400 of 697

Alzheimer's disease biomarkers: correspondence between human studies and animal models
Sabbagh, J. J., Kinney, J. W., & Cummings, J. L. (2013) · Neurobiology of Disease · doi:10.1016/j.nbd.2013.04.010 · Cited by 27
“strong sensitivity and specificity (Camus et al., 2012; Fleisher et al., 2011; Wong et al., 2010).”
BackgroundInfluential
New Molecular Targets for PET and SPECT Imaging in Neurodegenerative Diseases
Benadiba, M., Luurtsema, G., Wichert‐Ana, L., Buchpiguel, C. A., & Busatto, G. F. (2012) · Brazilian Journal of Psychiatry · doi:10.1016/j.rbp.2012.07.002 · Cited by 29
Evaluation of the early-phase [18F]AV45 PET as an optimal surrogate of [18F]FDG PET in ageing and Alzheimer’s clinical syndrome
Vanhoutte, M., Landeau, B., Sherif, S., Sayette, V. D. L., Dautricourt, S., Abbas, A., Manrique, A., Chocat, A., & Chételat, G. (2021) · NeuroImage Clinical · doi:10.1016/j.nicl.2021.102750 · Cited by 26
Tracer‐specific reference tissues selection improves detection of 18F‐FDG , 18F ‐florbetapir, and 18F ‐flortaucipir PET SUVR changes in Alzheimer's disease
Li, Y., Ng, Y. L., Paranjpe, M. D., Ge, Q., Gu, F., Li, P., Yan, S., Lu, J., Wang, X., Zhou, Y., et al. (2022) · Human Brain Mapping · doi:10.1002/hbm.25774 · Cited by 25
“…while the 18 F-florbetapir and 18 F-flortaucipir SUVRs can be used to approximate the tracer distribution volume ratio (DVR) of binding to A β and tau, respectively (Wong et al., 2010; Zhou et al., 2021; Zhou, Endres, Bra š i (cid:1) c, Huang, & Wong, 2003; Zhou, Sojkova, Resnick, & Wong, 2012).”
Self-citation
Performance of 11C-Pittsburgh Compound B PET Binding Potential Images in the Detection of Amyloid Deposits on Equivocal Static Images
Hosokawa, C., Ishii, K., Kimura, Y., Hyodo, T., Hosono, M., Sakaguchi, K., Usami, K., Shimamoto, K., Yamazoe, Y., & Murakami, T. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.156414 · Cited by 26
Sulfotransferase 1A3/4 copy number variation is associated with neurodegenerative disease
Butcher, N. J., Horne, M. K., Mellick, G. D., Fowler, C. J., Masters, C. L., & Minchin, R. F. (2017) · The Pharmacogenomics Journal · doi:10.1038/tpj.2017.4 · Cited by 26
Imaging Biomarkers in Alzheimer’s Disease: A Practical Guide for Clinicians
Sheikh‐Bahaei, N., Sajjadi, S. A., Manavaki, R., & Gillard, J. H. (2017) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-170013 · Cited by 29
“Of these, the 18F-labelled PiB analogue, 18F-flutemetamol [71] (GE-067; VizamylTM, GE Healthcare), the stilbene derivative 18F-florbetapir [72] (AV-45; AMYViDTM, Eli Lilly), and the strylpyridine derivative 18Fflorbetaben [73] (BAY-94-9172; NeuraceqTM, Piramal) have all gained approval from the US Food and Drug Admini…”
Background
Do You Want to Hear the Bad News? The Value of Diagnostic Tests for Alzheimer’s Disease
Mühlbacher, A. C., Johnson, F. R., Yang, J., Happich, M., & Belger, M. A. (2016) · Value in Health · doi:10.1016/j.jval.2015.10.011 · Cited by 25
Large-Scale Production of 119m Te and 119 Sb for Radiopharmaceutical Applications
Bennett, K. T., Bone, S., Akin, A. C., Birnbaum, E. R., Blake, A. V., Brugh, M., Daly, S. R., Engle, J. W., Fassbender, M. E., Ferrier, M. G., et al. (2019) · ACS Central Science · doi:10.1021/acscentsci.8b00869 · Cited by 25
The RSNA QIBA Profile for Amyloid PET as an Imaging Biomarker for Cerebral Amyloid Quantification
Smith, A. M., Obuchowski, N. A., Foster, N. L., Klein, G., Mozley, P. D., Lammertsma, A. A., Wahl, R. L., Sunderland, J. J., Vanderheyden, J., Benzinger, T. L. S., et al. (2022) · Journal of Nuclear Medicine · doi:10.2967/jnumed.122.264031 · Cited by 25
Self-citation
Operationalizing the centiloid scale for [ 18 F]florbetapir PET studies on PET/MRI
Coath, W., Marc Modat, A., Cardoso, M. J., Markiewicz, P. J., Lane, C., Parker, T. D., Keshavan, A., Buchanan, S. M., Keuss, S. E., Harris, M., et al. (2023) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12434 · Cited by 26
Imaging Approaches for Dementia
Murray, A. D. (2011) · American Journal of Neuroradiology · doi:10.3174/ajnr.a2782 · Cited by 26
BDNF Val66Met in preclinical Alzheimer's disease is associated with short-term changes in episodic memory and hippocampal volume but not serum mBDNF
Lim, Y. Y., Rainey‐Smith, S. R., Lim, Y. P., Laws, S. M., Gupta, V. B., Porter, T., Bourgeat, P., Ames, D. J., Fowler, C. J., Salvado, O., et al. (2017) · International Psychogeriatrics · doi:10.1017/s1041610217001284 · Cited by 24
“PET methodology has been described in detail previously (Rowe et al., 2010; Vandenberghe et al., 2010; Wong et al., 2010).”
Method
Current Role for Biomarkers in Clinical Diagnosis of Alzheimer Disease and Frontotemporal Dementia
Sheikh‐Bahaei, N., Sajjadi, S. A., & Pierce, A. L. (2017) · Current Treatment Options in Neurology · doi:10.1007/s11940-017-0484-z · Cited by 28
Enhancement of Binding Affinity for Amyloid Aggregates by Multivalent Interactions of 99mTc-Hydroxamamide Complexes
Iikuni, S., Ono, M., Watanabe, H., Matsumura, K., Yoshimura, M., Harada, N., Kimura, H., Nakayama, M., & Saji, H. (2014) · Molecular Pharmaceutics · doi:10.1021/mp400499y · Cited by 24
Head-to-Head Comparison of 18F-Florbetaben and 18F-Flutemetamol in the Cortical and Striatal Regions
Cho, S. H., Choe, Y. S., Kim, Y. J., Kim, H. J., Jang, H., Kim, Y., Kim, S. E., Kim, S. J., Kim, J. P., Jung, Y. H., et al. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200079 · Cited by 25
Molecular Imaging of Alzheimer Disease Pathology
Kantarci, K. (2014) · American Journal of Neuroradiology · doi:10.3174/ajnr.a3847 · Cited by 24
Multitarget Approach to Drug Candidates against Alzheimer’s Disease Related to AChE, SERT, BACE1 and GSK3β Protein Targets
Ivanova, L. B., Karelson, M. M., & Dobchev, D. A. (2020) · Molecules · doi:10.3390/molecules25081846 · Cited by 23
“The undergoing research on the discovery of novel therapeutics is targeting different molecular mechanisms and phenomena [1] including to amyloid deposition [4], astrogliosis [5], tau protein hyperphosphorylation and accumulation [6], neuronal dystrophy [7], oxidative stress [8], biometal dyshomeostasis, decline in ac…”
Background
Effect of C-terminus amidation of Aβ 39–42 fragment derived peptides as potential inhibitors of Aβ aggregation
Kapadia, A., Patel, A., Sharma, K. K., Maurya, I. K., Singh, V., Khullar, M., & Jain, R. (2020) · RSC Advances · doi:10.1039/d0ra04788k · Cited by 23
Regional uptakes from early-frame amyloid PET and 18F-FDG PET scans are comparable independent of disease state
Myoraku, A., Klein, G., Landau, S., Tosun, D., & Initiative, A. D. N. (2022) · European Journal of Hybrid Imaging · doi:10.1186/s41824-021-00123-0 · Cited by 26
Brain Networks, Clinical Manifestations, and Neuroimaging of Cognitive Disorders
Bonakdarpour, B., & Takarabe, C. (2022) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2022.07.004 · Cited by 23
Insight on AV-45 binding in white and grey matter from histogram analysis: a study on early Alzheimer’s disease patients and healthy subjects
Nemmi, F., Saint‐Aubert, L., Adel, D., Salabert, A., Pariente, J., Barbeau, E. J., Payoux, P., & Péran, P. (2014) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-014-2728-4 · Cited by 26
Synthesis and Evaluation of 5-Fluoro-2-aryloxazolo[5,4-b]pyridines as β-Amyloid PET Ligands and Identification of MK-3328
Harrison, S. T., Mulhearn, J. J., Wolkenberg, S. E., Miller, P. J., O'Malley, S. S., Zeng, Z., Williams, D. L., Hostetler, E. D., Bohorquez, S. M. S., Gammage, L., et al. (2011) · ACS Medicinal Chemistry Letters · doi:10.1021/ml200018n · Cited by 23
Dynamic PET and SPECT imaging with radioiodinated, amyloid-reactive peptide p5 in mice: A positive role for peptide dehalogenation
Martin, E. B., Kennel, S. J., Richey, T., Wooliver, C., Osborne, D., Williams, A. D., Stuckey, A. C., & Wall, J. S. (2014) · Peptides · doi:10.1016/j.peptides.2014.07.024 · Cited by 23
Is in vivo amyloid distribution asymmetric in primary progressive aphasia?
Martersteck, A., Murphy, C., RADEMAKER, A. W., Wieneke, C. A., Weıntraub, S., Chen, K., Mesulam, M. M., Rogalski, E. J., & Initiative, A. D. N. (2015) · Annals of Neurology · doi:10.1002/ana.24566 · Cited by 23
Insight into the Molecular Imaging of Alzheimer’s Disease
Arora, A., & Bhagat, N. (2016) · International Journal of Biomedical Imaging · doi:10.1155/2016/7462014 · Cited by 23
Investigation of white matter PiB uptake as a marker of white matter integrity
Zeydan, B., Schwarz, C. G., Lowe, V. J., Reid, R. I., Przybelski, S. A., Lesnick, T. G., Kremers, W. K., Senjem, M. L., Gunter, J. L., Min, H.-K. P., et al. (2019) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.741 · Cited by 23
Novel PET/SPECT Probes for Imaging of Tau in Alzheimer’s Disease
Watanabe, H., Ono, M., & Saji, H. (2015) · The Scientific World JOURNAL · doi:10.1155/2015/124192 · Cited by 22
Preclinical evaluation of [18F]D3FSP, deuterated AV-45, for imaging of β-amyloid in the brain
Zha, Z., Plöessl, K., Choi, S., Alexoff, D., & Kung, H. F. (2020) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2020.03.003 · Cited by 22
Self-citation
Benzodiazepine use and neuroimaging markers of Alzheimer’s disease in nondemented older individuals: an MRI and 18F Florbetapir PET study in the MEMENTO cohort
Gallet, Q., Bouteloup, V., Locatelli, M., Habert, M., Marie Chupin, A., Delrieu, J., Lebouvier, T., Robert, G., David, R., Bulteau, S., et al. (2021) · Neuropsychopharmacology · doi:10.1038/s41386-021-01246-5 · Cited by 22
Brain [18F]FDDNP Binding and Glucose Metabolism in Advanced Elderly Healthy Subjects and Alzheimer's Disease Patients
Tauber, C., Beaufils, É., Hommet, C., Ribeiro, M. J., Vercouillie, J., Vierron, E., Mondon, K., Cottier, J., Gissot, V., Guilloteau, D., et al. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-122068 · Cited by 23
Diphenylpropynone derivatives as probes for imaging β-amyloid plaques in Alzheimer’s brains
Ono, M., Watanabe, H., Watanabe, R., Haratake, M., Nakayama, M., & Saji, H. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.11.058 · Cited by 22
Applications of In Vivo Imaging in the Evaluation of the Pathophysiology of Viral and Bacterial Infections and in Development of Countermeasures to BSL3/4 Pathogens
Bocan, T. M. A., Panchal, R. G., & Bavari, S. (2014) · Molecular Imaging and Biology · doi:10.1007/s11307-014-0759-7 · Cited by 22
Visual paired associate learning deficits associated with elevated beta-amyloid in cognitively normal older adults.
Baker, J. E., Pietrzak, R. H., Laws, S. M., Ames, D. J., Villemagne, V. L., Rowe, C. C., Masters, C. L., Maruff, P. T., & Lim, Y. Y. (2019) · Neuropsychology · doi:10.1037/neu0000561 · Cited by 22
Clinical evaluation of [18F] JNJ-64326067, a novel candidate PET tracer for the detection of tau pathology in Alzheimer’s disease
Schmidt, M. E., Janssens, L., Moechars, D., Rombouts, F. J. R., Timmers, M., Barret, O., Constantinescu, C. C., Madonia, J., Russell, D., Sandiego, C. M., et al. (2020) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-020-04880-1 · Cited by 22
Comparison of standardized uptake value ratio calculations in amyloid positron emission tomography brain imaging
Knešaurek, K., Warnock, G., Kostakoğlu, L., Burger, C., & Initiative, A. D. N. (2018) · World Journal of Nuclear Medicine · doi:10.4103/wjnm.wjnm_5_17 · Cited by 21
Advancements of the sFIDA method for oligomer‐based diagnostics of neurodegenerative diseases
Kulawik, A., Heise, H., Zafiu, C., Willbold, D., & Bannach, O. (2018) · FEBS Letters · doi:10.1002/1873-3468.12983 · Cited by 21
Beta-amyloid (Aβ) uptake by PET imaging in older HIV+ and HIV- individuals
Mohamed, M. A., Skolasky, R. L., Zhou, Y., Ye, W., Brašić, J. R., Brown, A. M., Pardo, C. A., Barker, P. B., Wong, D. F., & Sacktor, N. C. (2020) · Journal of NeuroVirology · doi:10.1007/s13365-020-00836-1 · Cited by 21
Self-citation
Radiation dosimetry of florbetapir F 18
Joshi, A. D., Pontecorvo, M. J., Adler, L. P., Stabin, M. G., Skovronsky, D., Carpenter, A. P., Mintun, M. A., & Florbetapir F 18 study investigators (2014) · EJNMMI Research · doi:10.1186/2191-219x-4-4 · Cited by 21
Self-citation
6-Methoxy-indanone derivatives as potential probes for β-amyloid plaques in Alzheimer's disease
Nan, D., Gan, C., Wang, C.-W., Qiao, J., Wang, X.-M., & Zhou, J. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.07.069 · Cited by 21
An Automated Pipeline for the Analysis of PET Data on the Cortical Surface
Marcoux, A., Burgos, N., Bertrand, A., Teichmann, M., Routier, A., Wen, J., Samper‐Gonzàlez, J., Bottani, S., Durrleman, S., Habert, M., et al. (2018) · Frontiers in Neuroinformatics · doi:10.3389/fninf.2018.00094 · Cited by 22
Novel 99mTc-2-arylimidazo[2,1-b]benzothiazole derivatives as SPECT imaging agents for amyloid-β plaques
Molavipordanjani, S., Emami, S., Mardanshahi, A., Amiri, F. T., Noaparast, Z., & Hosseinimehr, S. J. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.04.069 · Cited by 21
AMYQ: An index to standardize quantitative amyloid load across PET tracers
Pegueroles, J., Montal, V., Bejanin, A., Vilaplana, E., Aranha, M. R., Santos‐Santos, M., Alcolea, D. A., Carrió, I., Camacho, V., Blesa, R., et al. (2021) · Alzheimer s & Dementia · doi:10.1002/alz.12317 · Cited by 21
ACR Appropriateness Criteria® Dementia: 2024 Update
Soderlund, K. A., Austin, M. J., Ben‐Haim, S., Chu, S., Ivanidze, J., Joshi, P., Kalnins, A., Kennedy, M., Kulshreshtha, A., Kuo, P. H., et al. (2025) · Journal of the American College of Radiology · doi:10.1016/j.jacr.2025.02.031 · Cited by 22
Harnessing the Immune System for Treatment and Detection of Tau Pathology
Congdon, E. E., Krishnaswamy, S., & Sigurdsson, E. M. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-132435 · Cited by 20
Advances in CNS Imaging Agents: Focus on PET and SPECT Tracers in Experimental and Clinical Use
George, N., Gean, E. G., Nandi, A., Фролов, Б. А., Zaidi, E., Lee, H., Brašić, J. R., & Wong, D. F. (2015) · CNS Drugs · doi:10.1007/s40263-015-0237-z · Cited by 21
“100 % specificity in end-of-life patients whose brains were also examined at autopsy [11].”
BackgroundInfluentialSelf-citation
Covariance-based vs. correlation-based functional connectivity dissociates healthy aging from Alzheimer disease
Strain, J. F., Brier, M. R., Tanenbaum, A., Gordon, B. A., McCarthy, J. E., Dincer, A., Marcus, D. S., Chhatwal, J. P., Graff‐Radford, N. R., Day, G. S., et al. (2022) · NeuroImage · doi:10.1016/j.neuroimage.2022.119511 · Cited by 24
Imaging Methods Applicable in the Diagnostics of Alzheimer’s Disease, Considering the Involvement of Insulin Resistance
Hnilicová, P., Kantorová, E., Šutovský, S., Grofik, M., Zeleňák, K., Kurča, E., Žilka, N., Parvanovova, P., & Kolísek, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043325 · Cited by 21
18F-FDG and 18F-Florbetapir PET in Clinical Practice
Bailly, M., Ribeiro, M. J., Vercouillie, J., Hommet, C., Gissot, V., Camus, V., & Guilloteau, D. (2014) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000000666 · Cited by 20
ACR Appropriateness Criteria Dementia and Movement Disorders.
Wippold, F., Brown, D. C. S., Broderick, D., Burns, J., Corey, A., Deshmukh, T. K., Douglas, A. C., Holloway, K., Jagadeesan, B., Jurgens, J. S., et al. (2015) · Journal of the American College of Radiology · doi:10.1016/j.jacr.2014.09.025 · Cited by 49
Novel Indanone Derivatives as Potential Imaging Probes for β‐Amyloid Plaques in the Brain
Qiao, J., Gan, C., Wang, C., Ge, J., Nan, D., Pan, J., & Zhou, J. (2012) · ChemBioChem · doi:10.1002/cbic.201200223 · Cited by 20
Preclinical Characterization of a Novel Class of18F-Labeled PET Tracers for Amyloid-β
Brockschnieder, D., Schmitt‐Willich, H., Heinrich, T. K., Varrone, A., Gulyás, B. Z., Tóth, M., Andersson, J. D., Boemer, U., Krause, S., Friebe, M., et al. (2012) · Journal of Nuclear Medicine · doi:10.2967/jnumed.112.104810 · Cited by 20
Synthesis and evaluation of a 18F-labeled spirocyclic piperidine derivative as promising σ1 receptor imaging agent
Chen, Y., Wang, X., Zhang, J., Deuther‐Conrad, W., Zhang, X., Huang, Y. H., Li, Y., Ye, J.-J., Cui, M., Steinbach, J., et al. (2014) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2014.08.003 · Cited by 19
Low background and high contrast PET imaging of amyloid-β with [11C]AZD2995 and [11C]AZD2184 in Alzheimer’s disease patients
Forsberg, A., Juréus, A., Cselényi, Z., Eriksdotter, M., Freund‐Levi, Y., Jeppsson, F., Swahn, B., Sandell, J., Julin, P., Schou, M., et al. (2013) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-012-2322-6 · Cited by 19
Impact of partial volume correction on the regional correspondence between in vivo [C-11]PiB PET and postmortem measures of Aβ load
Minhas, D. S., Price, J. C., Laymon, C. M., Becker, C. R., Klunk, W. E., Tudorascu, D., Abrahamson, E. E., Hamilton, R. L., Kofler, J., Mathis, C. A., et al. (2018) · NeuroImage Clinical · doi:10.1016/j.nicl.2018.04.007 · Cited by 21
“To facilitate clinical diagnosis and early disease detection, several positron emission tomography (PET) radioligands were developed for imaging Aβ pathology in vivo, including 11C-radiolabelled Pittsburgh Compound B ([C-11]PiB) [3, 4], 18FFlorbetapir [5], 18F-Flutemetamol [6], and 18F-florbetaben [7], the latter thre…”
Kinetic isotope effects and synthetic strategies for deuterated carbon-11 and fluorine-18 labelled PET radiopharmaceuticals
Klenner, M. A., Pascali, G., Fraser, B. H., & Darwish, T. A. (2021) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2021.03.011 · Cited by 18
99mTc-labeled-2-arylbenzoxazole derivatives as potential Aβ imaging probes for single-photon emission computed tomography
Wang, X., Cui, M., Jia, J., & Liu, B. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.10.046 · Cited by 19
Imaging of Cerebral Amyloid Angiopathy with Bivalent 99mTc-Hydroxamamide Complexes
Iikuni, S., Ono, M., Watanabe, H., Matsumura, K., Yoshimura, M., Kimura, H., Ishibashi‐Ueda, H., Okamoto, Y., Ihara, M., & Saji, H. (2016) · Scientific Reports · doi:10.1038/srep25990 · Cited by 19
Optimal Target Region for Subject Classification on the Basis of Amyloid PET Images
Carbonell, F., Zijdenbos, A. P., Charil, A., Grand’Maison, M., & Bedell, B. J. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.158774 · Cited by 19
Unveiling Molecular Events in the Brain by Noninvasive Imaging
Klohs, J., & Rudin, M. (2011) · The Neuroscientist · doi:10.1177/1073858410383433 · Cited by 22
Analyzing heterogeneity in Alzheimer disease using multimodal normative modeling on imaging‐based ATN biomarkers
Kumar, S., Earnest, T., Yang, B., Kothapalli, D., Aschenbrenner, A. J., Hassenstab, J. J., Xiong, C., Ances, B. M., Morris, J. C., Benzinger, T. L. S., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70143 · Cited by 20
“Even within similar CDR groups (e.g., CDR = 0 andCDR = 0.5),ADNIparticipantsexhibitedgreaterhippocampalatro-phy and tau burden, while amyloid Centiloid values were comparable (Figure S8).”
Influential
Structural and mechanistic insights into the inhibition of amyloid-β aggregation by Aβ39-42 fragment derived synthetic peptides
Kapadia, A., Sharma, K. K., Maurya, I. K., Singh, V., Khullar, M., & Jain, R. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.113126 · Cited by 19
Tracer development for PET imaging of proteinopathies
Kallinen, A., & Kassiou, M. (2022) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2022.04.001 · Cited by 18
Organofluorine Compounds in Neurological Disorders
Reddy, V. (2015) · Elsevier eBooks · doi:10.1016/b978-0-444-53748-5.00008-3 · Cited by 2
Highly efficient solid phase supported radiosynthesis of [11C]PiB using tC18 cartridge as a “3‐in‐1” production entity
Boudjemeline, M., Hopewell, R., Rochon, P., Jolly, D., Hammami, I., Villeneuve, S., & Kostikov, A. P. (2017) · Journal of Labelled Compounds and Radiopharmaceuticals · doi:10.1002/jlcr.3569 · Cited by 18
Down syndrome: Distribution of brain amyloid in mild cognitive impairment
Keator, D., Phelan, M. J., Taylor, L., Doran, E., Krinsky-McHale, S., Price, J., Ballard, E., Kreisl, W., Hom, C., Nguyen, D. D., et al. (2020) · Alzheimer's & Dementia · doi:10.1002/dad2.12013 · Cited by 19
Neuronal insulin signaling and brain structure in nondemented older adults: the Atherosclerosis Risk in Communities Study
Walker, K. A., Chawla, S., Nogueras‐Ortiz, C. J., Coresh, J., Sharrett, A. R., Wong, D. F., Jack, C. R., Spychalla, A. J., Gottesman, R. F., & Kapogiannis, D. (2020) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2020.09.022 · Cited by 18
Self-citation
Perspectives in Molecular Imaging Using Staging Biomarkers and Immunotherapies in Alzheimer’s Disease
Leclerc, B., & Abulrob, A. (2013) · The Scientific World JOURNAL · doi:10.1155/2013/589308 · Cited by 18
Relative Equilibrium Plot Improves Graphical Analysis and Allows Bias Correction of Standardized Uptake Value Ratio in Quantitative11C-PiB PET Studies
Zhou, Y., Sojkova, J., Resnick, S. M., & Wong, D. F. (2012) · Journal of Nuclear Medicine · doi:10.2967/jnumed.111.095927 · Cited by 18
“Relative equilibrium tracer kinetics were also observed in 11Craclopride for dopamine D2-like receptor imaging (17,25), 2-(1-{6-[(2-18F-fluoroethyl)(methyl)amino]-2-naphthylethylidene) malononitrile} (18F-FDDNP) for imaging b-amyloid plaques and neurofibrillary tangles (37), and 18F-florbetapir and 18F-florbetaben for…”
MethodSelf-citation
Development of tau PET Imaging Ligands and their Utility in Preclinical and Clinical Studies
Choi, Y., Ha, S., Lee, Y., Kim, Y. K., Lee, D. S., & Kim, D. J. (2017) · Nuclear Medicine and Molecular Imaging · doi:10.1007/s13139-017-0484-7 · Cited by 18
Multimodal surface-based transformer model for early diagnosis of Alzheimer’s disease
Duong, Q. A., Tran, S. D., & Gahm, J. K. (2025) · Scientific Reports · doi:10.1038/s41598-025-90115-y · Cited by 17
The role of neuroimaging in Alzheimer’s disease: implications for the diagnosis, monitoring disease progression, and treatment
Mulumba, J., Duan, R., Luo, B., Wu, J., Sulaiman, M., Wang, F., & Yang, Y. (2025) · Exploration of neuroscience · doi:10.37349/en.2025.100675 · Cited by 23
Emerging Biomarkers in Cognition
Wicklund, M. R., & Petersen, R. C. (2013) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2013.07.006 · Cited by 17
Visualization and Quantification of 3-Dimensional Stereotactic Surface Projections for18F-Flutemetamol PET Using Variable Depth
Lilja, J., Thurfjell, L., & Sørensen, J. C. H. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.169169 · Cited by 17
“Because of the logistic limitations due to the short half-life of 11C, amyloid tracers using the longer-lived radiolabel 18F have been developed: 18Fflorbetapir (4,5), 18F-florbetaben (6,7), and 18F-flutemetamol (8,9), all approved in the United States and European Union, and the late-stage investigational amyloid ima…”
Background
Deep residual inception encoder‐decoder network for amyloid PET harmonization
Shah, J., Gao, F., Li, B., Ghisays, V., Luo, J., Chen, Y., Lee, W., Zhou, Y., Benzinger, T. L. S., Reiman, E. M., et al. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12564 · Cited by 16
Self-citation
Application of Haralick texture features in brain [18F]-florbetapir positron emission tomography without reference region normalization
Campbell, D. L., Kang, H., & Shokouhi, S. (2017) · Clinical Interventions in Aging · doi:10.2147/cia.s143307 · Cited by 20
Tactical Applications of Fluorine in Drug Design and Development
Meanwell, N. A., Eastman, K. J., & Gillis, E. P. (2014) · Springer eBooks · doi:10.1007/978-3-319-04346-3_1 · Cited by 17
Amyloid imaging: Coming to a PET scanner near you
Jagust, W. J. (2010) · Annals of Neurology · doi:10.1002/ana.22144 · Cited by 17
Neuroimaging and genetic risk for Alzheimer’s disease and addiction-related degenerative brain disorders
Roussotte, F. F., Daianu, M., Jahanshad, N., Leonardo, C. D., & Thompson, P. M. (2013) · Brain Imaging and Behavior · doi:10.1007/s11682-013-9263-y · Cited by 16
Core Binding Site of a Thioflavin-T-Derived Imaging Probe on Amyloid β Fibrils Predicted by Computational Methods
Kawai, R., Araki, M., Yoshimura, M., Kamiya, N., Ono, M., Saji, H., & Okuno, Y. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.7b00389 · Cited by 16
Hybrid PET-MRI in Alzheimer’s Disease Research
Mainta, I., Vargas, M. I., Trombella, S., Frisoni, G. B., Unschuld, P. G., & Garibotto, V. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-7704-8_12 · Cited by 16
Supervoxels-Based Histon as a New Alzheimer’s Disease Imaging Biomarker
Ortiz-Toro, C. A., Gonzalo‐Martín, C., García‐Pedrero, Á., & Menasalvas, E. (2018) · Sensors · doi:10.3390/s18061752 · Cited by 16
Pursuit of precision medicine: Systems biology approaches in Alzheimer's disease mouse models
Gurdon, B., & Kaczorowski, C. C. (2021) · Neurobiology of Disease · doi:10.1016/j.nbd.2021.105558 · Cited by 16
Fluorine-18 labeling of three novel d-peptides by conjugation with N-succinimidyl-4-[18F]fluorobenzoate and preliminary examination by postmortem whole-hemisphere human brain autoradiography
Jahan, M., Nag, S., Красикова, Р. Н., Weber, U., Muhs, A., Pfeifer, A., Spenger, C., Willbold, D., Gulyás, B. Z., & Halldin, C. (2011) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2011.09.008 · Cited by 16
Biomarkers in Parkinson‘s Disease: A Funder‘s Perspective
Frasier, M. A., Chowdhury, S., Eberling, J. L., & Sherer, T. (2010) · Biomarkers in Medicine · doi:10.2217/bmm.10.89 · Cited by 16
Characterization of a Brain Permeant Fluorescent Molecule and Visualization of Aβ Parenchymal Plaques, Using Real-Time Multiphoton Imaging in Transgenic Mice
Sundaram, G. S. M., Garai, K., Rath, N. P., Yan, P., Cirrito, J. R., Cairns, N. J., Lee, J., & Sharma, V. (2014) · Organic Letters · doi:10.1021/ol501264q · Cited by 16
[ 11 C]PIB PET Is Associated with the Brain Biopsy Amyloid-β Load in Subjects Examined for Normal Pressure Hydrocephalus
Rinne, J. O., Suotunen, T., Rummukainen, J. K., Herukka, S., Nerg, O., Koivisto, A. M., Rauramaa, T. H., Någren, K., Hiltunen, M., Alafuzoff, I. I., et al. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-180645 · Cited by 16
Association of Head Injury with Brain Amyloid Deposition: The ARIC-PET Study
Schneider, A. L. C., Selvin, E., Liang, M., Latour, L. L., Turtzo, L. C., Koton, S., Coresh, J., Mosley, T. H., Whitlow, C. T., Zhou, Y., et al. (2019) · Journal of Neurotrauma · doi:10.1089/neu.2018.6213 · Cited by 16
Self-citation
Microglial activation, tau and amyloid deposition in TREM2 p.R47H carriers and mild cognitive impairment patients: a multi-modal/multi-tracer PET/MRI imaging study with influenza vaccine immune challenge
Cousins, O., Schubert, J. J., Chandra, A., Veronese, M., Valkimadi, P., Creese, B., Khan, Z., Arathimos, R., Hampshire, A., Rosenzweig, I., et al. (2023) · Journal of Neuroinflammation · doi:10.1186/s12974-023-02945-0 · Cited by 16
Discovery and Evaluation of Imidazo[2,1-b][1,3,4]thiadiazole Derivatives as New Candidates for α-Synuclein PET Imaging
Zeng, Q., Zhang, X., Li, Y., Zhang, Q., Dai, J., Yan, X., Liu, Y., Zhang, J., Liu, S., & Cui, M. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00686 · Cited by 15
Biomarkers for the clinical evaluation of the cognitively impaired elderly: amyloid is not enough
McEvoy, L. K., & Brewer, J. B. (2012) · Imaging in Medicine · doi:10.2217/iim.12.27 · Cited by 15
Imaging characteristics and safety of florbetapir (18F) in Japanese healthy volunteers, patients with mild cognitive impairment and patients with Alzheimer’s disease
Namiki, C., Takita, Y., Iwata, A., Momose, T., Senda, M., Okubo, Y., Joshi, A. D., Lu, M., Agbulos, A., Breault, C., et al. (2015) · Annals of Nuclear Medicine · doi:10.1007/s12149-015-0978-2 · Cited by 15
Self-citation
Utility of the 18F-Florbetapir positron emission tomography in systemic amyloidosis
Mestre-Torres, J., Lorenzo‐Bosquet, C., Cuberas‐Borrós, G., Gironella, M., Solans, R., Fernández‐Codina, A., Buján-Rivas, S., Castell‐Conesa, J., & Martínez‐Valle, F. (2018) · Amyloid · doi:10.1080/13506129.2018.1467313 · Cited by 15
“F-Florbetapir, a derivate of thioflavin-T, demonstrates high affinity and specificity to amyloid deposits with favorable pharmacokinetics [4], and successfully visualizes amyloid plaques in the brain of Alzheimer’s disease patients [5].”
Background
Reduced acquisition time PET pharmacokinetic modelling using simultaneous ASL–MRI: proof of concept
Scott, C. J., Jiao, J., Melbourne, A., Burgos, N., Cash, D. M., Vita, E. D., Markiewicz, P. J., O’Connor, A., Thomas, D. L., Weston, P. S. J., et al. (2018) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x18797343 · Cited by 15
Thiophene‐Based Optical Ligands That Selectively Detect Aβ Pathology in Alzheimer's Disease
Klingstedt, T., Shirani, H., Ghetti, B. F., Vidal, R., & Nilsson, K. P. R. (2021) · ChemBioChem · doi:10.1002/cbic.202100199 · Cited by 14
From frontotemporal lobar degeneration pathology to frontotemporal lobar degeneration biomarkers
Hales, C. M., & Hu, W. T. (2013) · International Review of Psychiatry · doi:10.3109/09540261.2013.776522 · Cited by 16
Synthesis and biological evaluation of radioiodinated quinacrine-based derivatives for SPECT imaging of Aβ plaques
Fuchigami, T., Kobashi, N., Haratake, M., Kawasaki, M., & Nakayama, M. (2012) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2012.12.020 · Cited by 15
Metal Protein-Attenuating Compound for PET Neuroimaging: Synthesis and Preclinical Evaluation of [11C]PBT2
Krishnan, H. S., Bernard‐Gauthier, V., Placzek, M. S., Dahl, K., Narayanaswami, V., Livni, E., Chen, Z., Yang, J., Collier, T. L., Ran, C., et al. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.7b00936 · Cited by 15
Effects of 18F-fluorinated neopentyl glycol side-chain on the biological characteristics of stilbene amyloid-β PET ligands
Tago, T., Toyohara, J., Fujimaki, R., Tatsuta, M., Song, R., Hirano, K., Iwai, K., & TANAKA, H. L. (2021) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2020.12.008 · Cited by 15
Florbetapir F 18 for brain imaging of beta-amyloid plaques
Romano, M., & Buratti, E. (2013) · Drugs of today · doi:10.1358/dot.2013.49.3.1937428 · Cited by 15

Authors: Wong, D. F., Rosenberg, P. B., Zhou, Y., Kumar, A., Raymont, V., Ravert, H. T., Dannals, R. F., Nandi, A., Brašić, J. R., Ye, W., Hilton, J., Lyketsos, C., Kung, H. F., Joshi, A. D., Skovronsky, D. M., & Pontecorvo, M. J.
Affiliations: Johns Hopkins University (US)
University of Pennsylvania (US)
Eli Lilly (United States) (US)
ORCID: Wong, Dean F.
Rosenberg, Paul B.
Zhou, Yun
Kumar, Anil
Raymont, Vanessa
Ravert, Hayden T.
Dannals, Robert F.
Nandi, Ayon
Brašić, James R.
Lyketsos, Constantine
Kung, Hank F.
Pontecorvo, Michael J.
Venue: Journal of Nuclear Medicine
Publisher: Society of Nuclear Medicine
Published: 2010-05-25
Volume: 51
Issue: 6
Pages: 913-920
ISSN: 0161-5505 (ISSN-L)
2159-662X
DOI: 10.2967/jnumed.109.069088
PMC: PMC3101877
OpenAlex: W2040174321
Cited by: 684
References: 35
Citations by year: 2026: 21 · 2025: 22 · 2024: 17 · 2023: 25 · 2022: 32 · 2021: 42 · 2020: 43 · 2019: 31 · 2018: 46 · 2017: 54 · 2016: 56 · 2015: 50 · 2014: 60 · 2013: 64 · 2012: 57
FWCI: 40.78
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Journal of Nuclear Medicine (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: Eli Lilly and Company
Pfizer
Vanderbilt University
National Institutes of Health
Avid Radiopharmaceuticals
National Institute on Alcohol Abuse and Alcoholism (R01AA012839, AA012839)
National Institute on Aging (K08AG029157, P50AG005146)
National Institute of Mental Health (R01MH078175, MH 078175)
National Institute on Drug Abuse (K24DA000412)
Topics: Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
Keywords: Alzheimer's disease, amyloid-beta deposition, 18F-florbetapir, positron emission tomography, radioligands, amyloid imaging, distribution volume ratio, standardized uptake value ratio, dynamic PET, tracer metabolism, brain amyloid imaging, late-life cognitive impairment, cerebellum
MeSH terms: Aged, Alzheimer Disease, Amyloid, Aniline Compounds, Brain, Ethylene Glycols, Female, Fluorine Radioisotopes, Humans, Male, Radiometry, Whole-Body Irradiation, Case-Control Studies, Positron-Emission Tomography, Drug-Related Side Effects and Adverse Reactions

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

In Vivo Imaging of Amyloid Deposition in Alzheimer Disease Using the Radioligand 18 F-AV-45 (Flobetapir F 18)

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks